Patent ID: 6268473
Filing Date: 2001-07-31
Classification: A61K,A61P,C07K

Abstract:
A substantially pure .alpha.-conotoxin peptide seleceted from the group consisting of:Xaa.sub.1 -Cys-Cys-Asn-Xaa.sub.2 -Ala-Cys-Gly-Arg-His-Xaa.sub.3 -Ser-Cys-Xaa.sub.4 -Gly (SEQ ID NO:3);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.4 -His-Phe-Ser-Cys (SEQ ID NO:4);Gly-Arg-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.2 -Asn-Xaa.sub.3 -Ser-Cys (SEQ ID NO:5);Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Arg-Xaa.sub.4 -Xaa.sub.3 -Asn-Cys (SEQ ID NO:6);Cys-Cys-Cys-Asn-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.2 -Asn-Xaa.sub.3 -Gly-Cys-Gly-Thr-Ser-Cys-Ser-Arg-Xaa.sub.2 -Ser-Xaa.sub.1 -Xaa.sub.2 -Arg-Arg (SEQ ID NO:7);Asn-Gly-His-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Gly-Xaa.sub.4 -Xaa.sub.3 -Val-Xaa.sub.4 -Cys (SEQ ID NO:8);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Gly-Xaa.sub.4 -Xaa.sub.3 -Val-Xaa.sub.4 -Cys (SEQ ID NO:9);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.4 -His-Phe-Ile-Cys (SEQ ID NO:10);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.4 -His-Phe-Ser-Cys (SEQ ID NO:11);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ser-Cys-Gly-Arg-Xaa.sub.4 -Xaa.sub.3 -Asn-Cys (SEQ ID NO:12);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Ala-Arg-Xaa.sub.4 -Xaa.sub.3 -Asn-Cys (SEQ ID NO:13);Asn-Xaa.sub.1 -Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Ala-Arg-Xaa.sub.4 -Xaa.sub.3 -Asn-Cys (SEQ ID NO:14);Asp-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Gln-Asn-Xaa.sub.3 -Ser-Cys (SEQ ID NO:15);Asp-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Ala-Xaa.sub.4 -His-Phe-Asn-Cys (SEQ ID NO:16);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Ala-Xaa.sub.4 -Asn-Xaa.sub.3 -Ser-Cys (SEQ ID NO:17);Asn-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Ala-Arg-Xaa.sub.4 -Xaa.sub.3 -Ser-Cys (SEQ ID NO:18);Xaa.sub.5 -Cys-Cys-Asn-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.2 -Xaa.sub.4 -Xaa.sub.3 -Ser-Cys (SEQ ID NO:19);Xaa.sub.5 -Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Xaa.sub.4 -Xaa.sub.4 -Xaa.sub.3 -Asn-Cys (SEQ ID NO:20);Ser-Gly-Arg-Cys-Cys-His-Xaa.sub.2 -Ala-Cys-Gly-Arg-Xaa.sub.4 -Xaa.sub.3 -Asn-Cys (SEQ ID NO:21);Arg-Asp-Xaa.sub.2 -Cys-Cys-Ser-Asn-Xaa.sub.2 -Val-Cys-Thr-Val-His-Asn-Xaa.sub.2 -Gln-Ile-Cys (SEQ ID NO:22);Arg-Ala-Cys-Cys-Ser-Xaa.sub.3 -Xaa.sub.2 -Xaa.sub.2 -Cys-Asn-Val-Asn-Xaa.sub.3 -Xaa.sub.2 -Xaa.sub.1 -Ile-Cys (SEQ ID NO:23);Gly-Gly-Cys-Cys-Ser-Xaa.sub.3 -Xaa.sub.2 -Xaa.sub.2 -Cys-Asn-Val-Ser-Xaa.sub.3 -Xaa.sub.2 -Xaa.sub.1 -Ile-Cys (SEQ ID NO:24);Ser-Leu-Leu-Cys-Cys-Thr-Ile-Xaa.sub.2 -Ser-Cys-Xaa.sub.4 -Ala-Ser-Xaa.sub.3 -Xaa.sub.2 -Asp-Ile-Cys (SEQ ID NO:27),wherein Xaa.sub.1 is Glu or .gamma.-carboxy-glutamate (Gla); Xaa.sub.2 is Pro or hydroxy-Pro; Xaa.sub.3 is Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; Xaa.sub.4 is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa.sub.5 is Gln or pyro-Glu; and the C-terminus contains a carboxyl or amide group, the polypeptide being substantially free of other peptides.